The Manufacturers Life Insurance Company Has $1.26 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

The Manufacturers Life Insurance Company trimmed its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 33.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,684 shares of the biopharmaceutical company’s stock after selling 10,938 shares during the period. The Manufacturers Life Insurance Company’s holdings in Xenon Pharmaceuticals were worth $1,261,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Avoro Capital Advisors LLC increased its position in shares of Xenon Pharmaceuticals by 0.5% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock worth $243,124,000 after acquiring an additional 24,444 shares in the last quarter. Janus Henderson Group PLC lifted its position in Xenon Pharmaceuticals by 3.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,084,034 shares of the biopharmaceutical company’s stock valued at $183,110,000 after acquiring an additional 140,149 shares in the last quarter. Wellington Management Group LLP lifted its position in Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after acquiring an additional 1,435,096 shares in the last quarter. Capital International Investors boosted its stake in Xenon Pharmaceuticals by 7.3% during the 4th quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after purchasing an additional 233,466 shares during the last quarter. Finally, Commodore Capital LP boosted its stake in Xenon Pharmaceuticals by 30.1% during the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after purchasing an additional 700,000 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

XENE has been the subject of a number of recent research reports. Wall Street Zen raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Wells Fargo & Company reaffirmed an “overweight” rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Royal Bank Of Canada decreased their price target on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a report on Friday. HC Wainwright reissued a “buy” rating and issued a $74.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday. Finally, JPMorgan Chase & Co. raised their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $77.13.

Xenon Pharmaceuticals Stock Down 1.6%

Shares of XENE stock opened at $63.22 on Wednesday. The company has a 50 day moving average of $60.67 and a 200-day moving average of $54.62. Xenon Pharmaceuticals Inc. has a 12-month low of $35.10 and a 12-month high of $72.66. The firm has a market cap of $6.11 billion, a P/E ratio of -13.34 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same period in the previous year, the company posted ($1.07) earnings per share. As a group, equities analysts expect that Xenon Pharmaceuticals Inc. will post -4.91 EPS for the current year.

Trending Headlines about Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $74 price target, above the stock’s recent trading level near $63. The firm raised its EPS forecasts for 2026 through 2030, including a narrower expected loss of $4.48 per share in fiscal 2026, $4.88 in 2027, $3.89 in 2028, $2.23 in 2029 and $0.18 in 2030. The revisions suggest the analyst expects Xenon’s losses to narrow faster than previously projected. HC Wainwright estimates for Xenon Pharmaceuticals
• Neutral Sentiment: Reported short-interest data showed zero shares sold short as of August 11, compared with zero shares in the prior reporting period, producing a zero-day days-to-cover ratio. Because the report also displays an invalid “NaN” percentage change, it offers no meaningful indication of changing bearish positioning or potential short-covering support.
• Negative Sentiment: Xenon is still expected to report substantial losses, with consensus fiscal-year EPS of negative $4.92 and HC Wainwright forecasting additional quarterly losses through 2027. As a development-stage biopharmaceutical company, XENE remains dependent on clinical and commercial execution, while the provided updates contain no new drug-development or regulatory catalyst. Equities Analysts Set Expectations for XENE Q1 Earnings

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares in the company, valued at approximately $77,318.70. This represents a 44.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director owned 24,896 shares in the company, valued at $1,322,973.44. This represents a 5.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.